Wall Street analyst estimates for Harvard Bioscience, Inc. (HBIO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 0.80 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.17 | ||
| 2026-08-11 | $-0.14 | $-0.21 | +33.3% |
| 2026-05-12 | $-0.33 | $-0.62 | +46.8% |
| 2026-03-12 | $-0.64 | $0.04 | -1700.0% |
| 2025-11-06 | $-0.28 | $0.05 | -652.0% |
| 2025-08-11 | $-0.10 | $-0.25 | +60.0% |
| 2025-05-12 | $-0.10 | $-0.20 | +50.0% |
| 2025-03-12 | $0.60 | $0.07 | +757.1% |
Valuation Ratios
| Price / Book | 4.86 |
| EV / EBITDA | -78.67 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $104.5M | $101.9M | $120.8M | $116.2M | $102.1M | $118.9M | $113.3M | $112.2M | $94.1M | $86.5M |
| Cost of Revenue | $56.1M | $54.3M | $57.6M | $51.9M | $44.1M | $51.3M | $52.5M | $46.2M | $39.4M | $40.7M |
| Gross Profit | $48.4M | $47.6M | $63.2M | $64.3M | $58.0M | $67.7M | $60.8M | $66.1M | $54.8M | $45.9M |
| Research & Development | $5.4M | $5.6M | $11.0M | $10.7M | $8.7M | $10.8M | $12.3M | $11.8M | $10.4M | $8.8M |
| Selling, General & Admin | $41.4M | $39.6M | $45.8M | $46.0M | $43.4M | $48.9M | $49.5M | $46.9M | $43.7M | $37.0M |
| Operating Expenses | $49.5M | $47.7M | $62.2M | $63.9M | $57.8M | $65.6M | $67.8M | $64.2M | $61.0M | $46.5M |
| Operating Income | -$3.0M | -$101000 | $984000 | $377000 | $221000 | $2.1M | -$6.9M | $1.9M | -$6.2M | -$629000 |
| EBITDA | $1.8M | -$101000 | $5.4M | $7.6M | $5.2M | $9.0M | $944000 | $8.0M | -$1.5M | -$46.5M |
| Interest Expense | $642000 | $713000 | $5.4M | $5.4M | $4.8M | $1.5M | $2.5M | $3.6M | $3.2M | $4.9M |
| Pre-tax Income | -$3.1M | -$2.1M | -$8.5M | -$5.5M | -$7.3M | -$140000 | -$9.2M | -$2.6M | -$11.7M | -$57.4M |
| Income Tax | $1.2M | -$1.2M | -$3.7M | -$815000 | $518000 | $148000 | $337000 | $859000 | $740000 | -$686000 |
| Net Income | -$4.3M | -$865000 | -$3.5M | -$4.7M | -$7.8M | -$288000 | -$9.5M | -$3.4M | -$12.4M | -$56.7M |
| EPS | $-1.30 | $-0.26 | $-0.97 | $-1.20 | $-2.00 | $-0.07 | $-2.30 | $-0.81 | $-2.80 | $-12.80 |
| EPS (Diluted) | $-1.30 | $-0.25 | $-0.95 | $-1.20 | $-2.00 | $-0.07 | $-2.30 | $-0.81 | $-2.80 | $-12.80 |
| Shares Outstanding (Diluted) | $3.4M | $3.5M | $3.6M | $3.8M | $3.9M | $4.0M | $4.1M | $4.2M | $4.4M | $4.4M |
Price
| Price | $7.97 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CLGN · COSM · FEMY · NCNA · NXGL · NXL · RVP
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of HBIO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks